Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab

For non-small-cell lung cancer (NSCLC) patients without established actionable alterations in genes such as EGFR or ALK, options for targeted therapy remain limited in clinical practice. About 5% of lung adenocarcinoma patients have tumors with ERBB2 genetic alterations, with even fewer patients har...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Chi-Wei, Chen, Mei-Yin, Tseng, Ching-Min, Lapke, Nina, Chen, Shu-Jen, Tan, Kien Thiam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071810/
https://www.ncbi.nlm.nih.gov/pubmed/32190395
http://dx.doi.org/10.1155/2020/9072173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071810/
https://www.ncbi.nlm.nih.gov/pubmed/32190395
http://dx.doi.org/10.1155/2020/9072173

Ejemplares similares